Meeting
2023 ASCO Annual Meeting
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.
Authors
Shipra Gandhi
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Shipra Gandhi , Peter A. J. Forsyth , Mateusz Opyrchal , Kamran A. Ahmed , Kristopher Attwood , Ellis Glenn Levine , Tracey L. O'Connor , Amy P. Early , Robert Alan Fenstermaker , Dheerendra Prasad , Kazuaki Takabe , Brian J. Czerniecki , Pawel Kalinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT04348747
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS1112)
DOI
10.1200/JCO.2023.41.16_suppl.TPS1112
Abstract #
TPS1112
Poster Bd #
332b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
First Author: Andreas Seeber
Poster
2018 ASCO Annual Meeting
A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.
First Author: Neelima Vidula
Poster
2023 ASCO Annual Meeting
Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes.
First Author: Gaia Griguolo
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price